B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.

about

Applied Protein and Molecular Techniques for Characterization of B Cell Neoplasms in Horses.Targeting CK2-driven non-oncogene addiction in B-cell tumors.

P2860

Q36211658-0C7CF802-DBB9-4D28-AF24-EF0C7C355E08 Q38797342-22998D95-AFCC-4B15-A77C-66FFF7A40907

P2860

B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.

Item

http://www.wikidata.org/entity/Q38124119

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

B-cell antigen receptor signal ...... d translational opportunities.

@en

type

Item

label

B-cell antigen receptor signal ...... d translational opportunities.

@en

prefLabel

B-cell antigen receptor signal ...... d translational opportunities.

@en

P1476

B-cell antigen receptor signal ...... d translational opportunities.

@en

P2093

Ronald J Hill

http://www.w3.org/2001/XMLSchema#string

Seng-Lai Tan

http://www.w3.org/2001/XMLSchema#string

Yan Lou

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Chronic lymphocytic leukemia

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Oncogenically active MYD88 mutations in human lymphoma

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents

P304

377-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08830185.2013.818141

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23886341

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.

about

P2860

P2860

B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921